LMR Partners LLP - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 105 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
LMR Partners LLP ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q1 2023$125,093
+145.3%
83,395
+86.4%
0.00%
+100.0%
Q3 2022$51,000
-28.2%
44,7330.0%0.00%0.0%
Q2 2022$71,000
-58.2%
44,733
-38.0%
0.00%
-75.0%
Q1 2021$170,000
+347.4%
72,194
+80.1%
0.00%
+300.0%
Q3 2020$38,000
-7.3%
40,083
-15.0%
0.00%0.0%
Q2 2020$41,00047,1570.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q3 2022
NameSharesValueWeighting ↓
BROADWOOD CAPITAL INC 34,935,485$55,198,0004.16%
Raffles Associates 1,930,536$3,050,0003.32%
Defender Capital, LLC. 5,131,935$8,108,0003.18%
Prescott General Partners LLC 1,851,851$2,926,0000.20%
DAFNA Capital Management LLC 140,000$221,0000.06%
Laurion Capital Management LP 2,422,367$3,827,0000.06%
Beirne Wealth Consulting Services, LLC 45,000$71,0000.05%
Fort Sheridan Advisors LLC 78,931$125,0000.04%
Long Focus Capital Management, LLC 215,000$340,0000.04%
MORGAN JESS S & CO INC 20,000$32,0000.03%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders